NCT06463535

Brief Summary

Patient grouping

  • Group 1 (Type 2 Diabetes Mellitus patients with CPD + SRP and Omega-3)
  • Group 2 (Type 2 Diabetes Mellitus patients with CPD + SRP) different clinical parameters were recorded ; plaque index (PI), gingival index (GI), probing depth (PD), and clinical attachment loss (CAL). 6.Omega-3 poly-unsaturated fatty acids (1000mg) was given as an adjunctive treatment daily for 6 months to group 2, starting 2 weeks after phase 1 therapy.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for not_applicable diabetes-mellitus

Timeline
Completed

Started Jun 2023

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 15, 2023

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 15, 2024

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2024

Completed
8 days until next milestone

First Submitted

Initial submission to the registry

June 9, 2024

Completed
9 days until next milestone

First Posted

Study publicly available on registry

June 18, 2024

Completed
Last Updated

June 18, 2024

Status Verified

June 1, 2024

Enrollment Period

10 months

First QC Date

June 9, 2024

Last Update Submit

June 14, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • Serum level of chemerin

    Serum level of chemerin

    6 months

Secondary Outcomes (4)

  • periodontal clinical parameters

    6 months

  • hba1c

    6 months

  • GCF level of chemerin

    6 months

  • periodontal clinical parameters

    6 months

Study Arms (2)

group I

EXPERIMENTAL

Type 2 Diabetes Mellitus patients with CPD + SRP and Omega-3

Drug: Omega 3Procedure: SRP alone

group II

ACTIVE COMPARATOR

Type 2 Diabetes Mellitus patients with CPD + SRP

Procedure: SRP alone

Interventions

SRP + OMEGA 3

group I
SRP alonePROCEDURE

Scaling and root planning

group Igroup II

Eligibility Criteria

Age25 Years - 55 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Patients had type 2 DM for more than 2 years (diagnosed according to the American Diabetes Association criteria), with no other systemic problem. •Subjects had 14 or more natural teeth, of which at least five had a site with probing pocket depth (PPD) ≥ 5 mm and clinical attachment level ≥ 3 mm. From this point, according to the American Academy of Periodontology, subjects with moderate to severe periodontitis were included

You may not qualify if:

  • Pregnant and breastfeeding women, smokers or former smokers, patients with other autoimmune or systemic disease, those patients who took antibiotics in the last 6 months and patients weren't willing to follow our study protocol or plaque regimen

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

British University in Egypt

Cairo, Egypt

Location

Related Publications (1)

  • Ghalwash D, Ammar A, Hamdy A, El-Gawish A. Impact of the Adjunctive Use of Omega-3 in Periodontitis Patients With Diabetes on Local and Systemic Chemerin Levels: A Randomized Clinical Trial. Int J Dent. 2025 Jul 30;2025:7927250. doi: 10.1155/ijod/7927250. eCollection 2025.

MeSH Terms

Conditions

Diabetes MellitusPeriodontal Diseases

Interventions

Docosahexaenoic Acids

Condition Hierarchy (Ancestors)

Glucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesMouth DiseasesStomatognathic Diseases

Intervention Hierarchy (Ancestors)

Fatty Acids, Omega-3Dietary Fats, UnsaturatedDietary FatsFatsLipidsFatty Acids, UnsaturatedFatty AcidsFish OilsOils

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
lecturer

Study Record Dates

First Submitted

June 9, 2024

First Posted

June 18, 2024

Study Start

June 15, 2023

Primary Completion

April 15, 2024

Study Completion

June 1, 2024

Last Updated

June 18, 2024

Record last verified: 2024-06

Locations